Janney Montgomery Scott’s Candel Therapeutics CADL Stock Holding History

Janney Montgomery Scott’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324K	Buy	31,472 +1,000	+3%	+$7.55K	﹤0.01%	2685
2026 Q1	$149K	Buy	30,472 +3,400	+13%	+$18.5K	﹤0.01%	2670
2025 Q4	$153K	Sell	27,072 -3,314	-11%	-$17.8K	﹤0.01%	2837
2025 Q3	$155K	Buy	30,386 +3,096	+11%	+$17.9K	﹤0.01%	2771
2025 Q2	$138K	Buy	27,290 +6,200	+29%	+$31.9K	﹤0.01%	2615
2025 Q1	$119K	Buy	21,090 +10,765	+104%	+$88K	﹤0.01%	2597
2024 Q4	$90K	Sell	10,325 -1,340	-11%	-$7.92K	﹤0.01%	2637
2024 Q3	$81K	Buy	11,665 +50	+0.4%	+$311	﹤0.01%	2593
2024 Q2	$72K	Buy	+11,615	New	+$87.2K	﹤0.01%	2548

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Janney Montgomery Scott's CADL Position: Q2 2026 in Review

Janney Montgomery Scott increased its Candel Therapeutics (CADL) stake by 3.3% in Q2 2026, buying an estimated $7.55K and bringing the position to 31,472 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

Janney Montgomery Scott first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Janney Montgomery Scott held 31,472 shares of Candel Therapeutics worth $324K as of Q2 2026.
Janney Montgomery Scott bought 1,000 Candel Therapeutics shares in Q2 2026, an estimated $7.55K.
Candel Therapeutics made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q2 2026, its #2685 holding.
Janney Montgomery Scott first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Janney Montgomery Scott's 13F filing for Q2 2026, filed 5 Aug 2026.